Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
Jeffrey J. Kooijman, Guido J.R. Zaman(GlaxoSmithKline (Netherlands)), Yusuke Kawase, Wilhelmina E. van Riel, Nicole Willemsen‐Seegers(Center for Translational Molecular Medicine), Yugo Narumi, Joost C.M. Uitdehaag(Center for Translational Molecular Medicine), Yvonne Grobben(Center for Translational Molecular Medicine), Jelle Dylus(Center for Translational Molecular Medicine), Martine B.W. Prinsen(Center for Translational Molecular Medicine), Janneke J.T.M. Melis, Antoon M. van Doornmalen(Center for Translational Molecular Medicine), Jeroen A.D.M. de Roos, Tessa J.J. de Bitter(Radboud University Nijmegen)
Cited by 22
Related Papers
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.
|Proceedings of the National Academy of Sciences|1995|502
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets
|British Journal of Pharmacology|2012|105
Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease
|Annals of Surgical Oncology|2019|67
Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications
|Cancers|2021|53
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines
|Nature Communications|2024|50